C110-19 Association of Pre-treatment Interstitial Lung Abnormalities in Patients With Locally Advanced Non-smell Lung Cancer With Risk for Immune Checkpoint Inhibitor Pneumonitis
Randomized trial investigates how pre-treatment lung conditions affect pneumonitis risk in advanced NSCLC, indicating important clinical implications.
Key Points
The study aims to determine if pre-treatment interstitial lung abnormalities increase the risk for immune checkpoint inhibitor pneumonitis in locally advanced NSCLC patients treated with chemoradiation.
Retrospective review of baseline chest CT scans from 97 patients enrolled in the Gateway project.
Patients underwent concurrent chemoradiation followed by a minimum of three months of immune checkpoint inhibitor therapy.
Interstitial lung abnormalities were classified based on Fleischner Society criteria.
The incidence of ICI pneumonitis in the cohort was 28%.
Traction bronchiectasis was strongly associated with ICI pneumonitis (OR 9.4; 95% CI: 1.9-47).
Ground-glass opacities also showed a significant association with ICI pneumonitis (OR 3.3; 95% CI: 1.22-8.9).